Drug Retail

This is the time of the year when strategists are busy sending out their annual outlooks. Here on the Global Investment Strategy team, we decided to go one step further. Rather than pontificating about what could happen in 2025, we decided to harness the power of the multiverse to tell you what did happen (in at least one highly representative timeline).

Next week, please join me for a Webcast on Tuesday, December 17 at 10:30 AM EST (3:30 PM GMT, 4:30 PM CET) to discuss the economy and financial markets.

And with that, I will sign off for the year. I wish you and your loved ones a very happy and healthy 2025. We will be back in the first week of January with our MacroQuant Model Update.

Overweight Shares of the S&P drug retail index shot higher this week after reports surfaced that Amazon had shelved plans for a long-considered entry into the prescription drug business. Such a move seemed logical following the company's move into private-label over-the-counter medicines last year and the more recent announcement of a partnership with JPMorgan and Berkshire Hathaway to enter the health insurance business. We have argued in the past that the competitive threat was overblown and, accordingly, argue that the removal of such a threat is no reason to be overly excited. Rather, we think investor focus should remain squarely on the fundamentals that have remained strong despite the index's fall. The sector's share of the consumer's wallet has barely changed since the share price slide began in 2015 (second panel) and both pharma manufacturing shipments and retail sales appear to have turned the corner (bottom panel). The resulting earnings growth should be the remedy to the index's ills; stay overweight The ticker symbols for the stocks in this index are: BLBG: S5DRUG - CVS, WBA. The Elephant Walking Out Of The Room The Elephant Walking Out Of The Room

Negative relative sales growth at retail drug stores has caused the S&P retail drug store index to underperform (top and second panels). However, the second derivative of the decline has turned positive, troughing early this year, but the sector's share of the consumer's wallet has barely changed since the share price slide began in 2015. Analysts' top line estimates have largely captured the modest improvements in the sales outlook; these pulled out of deflation last month for the first time since late-2016 (bottom panel). However, valuations have not followed suit, which appears to be the market assigning a too-high risk premium to the operating recovery. If, as we expect, sales at drug retailers have turned a corner, margins and multiples should expand, particularly since the industry has consolidated substantially since 2015. This should allow investors to recoup some of their losses. Stay overweight The ticker symbols for the stocks in this index are: BLBG: S5DRUG - CVS, WBA. The Right Prescription The Right Prescription

Drug retail relative valuations have divorced from bullish indicators of top and bottom-line performance. Retail sales momentum continues to accelerate. The ongoing hospital hiring frenzy is indicative of rising procedures, and provides a good indication for future prescription drug demand, and thus pharmacy retail sales. Importantly, drug retailers are gaining market share from hypermarkets (third panel), underscoring that they will receive a disproportionate share of rising store traffic. From a contrarian perspective, there appears to be little buy in to a positive sales view, given that analysts have pared back relative sales growth expectations (fourth panel). Meanwhile, investors have attached a massive risk premium to the group (bottom panel). There is room for both profit and multiple expansion, and we reiterate a high-conviction overweight. The ticker symbols for the stocks in this index are: BLBG: S5DRUG - CVS, WBA. bca.uses_in_2016_08_11_002_c1 bca.uses_in_2016_08_11_002_c1

The S&P retail drug store index has been undermined by concerns about the opaque pricing structure of its pharmacy benefits management arms, which has pushed relative valuations to extremely attractive levels. While it is difficult to forecast whether any major concessions will be made to appease health insurers, this focus is masking an increasingly upbeat picture for the rest of the core business. Consumers are allocating a record share of their spending to pharmacy-related items, continuing a trend in place for more than two decades. It is rare for relative performance to deviate from relative spending trends for long, as the latter provides a clear indication of the industry's ability to deliver better-than-market profitability. Importantly, drug retailers have retrenched in recent years, paving the way for solid same-store sales growth. Shorter-term performance indicators are even more upbeat, please see the next Insight. The ticker symbols for the stocks in this index are: BLBG: S5DRUG - CVS, WBA. bca.uses_in_2016_08_11_001_c1 bca.uses_in_2016_08_11_001_c1

The sinking global credit impulse warns that reflation has not overwhelmed deflationary forces. Financials will continue to suffer, while utilities and retail drug stores will benefit.

The retail drug store industry is enjoying a twin boost from both bullish cyclical and secular forces. The latter is reflected in the long-term advance in personal outlays at pharmacies, which likely reflects increased drug demand as a consequence of an aging population. From a cyclical perspective, the surge in health care sector hiring activity reflects increased health coverage and rising patient volumes. That is a boon for drug demand, and is consistent with rising store traffic. As a result, pharmacies should be able to continue lifting selling prices at a rapid clip, despite deep deflation in the overall corporate sector. The upshot is ongoing productivity gains, as measured by sales/employee, should support robust earnings performance and a relative valuation re-rating. Stay with a high-conviction overweight. The ticker symbols for the stocks in this index are: WBA, CVS. bca.uses_in_2016_02_26_001_c1 bca.uses_in_2016_02_26_001_c1